We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Viatris (VTRS) Dips More Than Broader Markets: What You Should Know
Read MoreHide Full Article
In the latest trading session, Viatris (VTRS - Free Report) closed at $15.03, marking a -0.92% move from the previous day. This move lagged the S&P 500's daily loss of 0.38%. Meanwhile, the Dow lost 0.5%, and the Nasdaq, a tech-heavy index, lost 0.05%.
Heading into today, shares of the generic drugmaker had lost 0.33% over the past month, outpacing the Medical sector's loss of 5.24% and the S&P 500's loss of 6.25% in that time.
Investors will be hoping for strength from Viatris as it approaches its next earnings release, which is expected to be February 28, 2022. In that report, analysts expect Viatris to post earnings of $0.82 per share. This would mark a year-over-year decline of 12.77%. Meanwhile, our latest consensus estimate is calling for revenue of $4.31 billion, up 18.97% from the prior-year quarter.
Investors might also notice recent changes to analyst estimates for Viatris. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. Viatris is currently sporting a Zacks Rank of #3 (Hold).
Looking at its valuation, Viatris is holding a Forward P/E ratio of 4.11. This valuation marks a discount compared to its industry's average Forward P/E of 23.48.
The Medical Services industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 155, which puts it in the bottom 40% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Viatris (VTRS) Dips More Than Broader Markets: What You Should Know
In the latest trading session, Viatris (VTRS - Free Report) closed at $15.03, marking a -0.92% move from the previous day. This move lagged the S&P 500's daily loss of 0.38%. Meanwhile, the Dow lost 0.5%, and the Nasdaq, a tech-heavy index, lost 0.05%.
Heading into today, shares of the generic drugmaker had lost 0.33% over the past month, outpacing the Medical sector's loss of 5.24% and the S&P 500's loss of 6.25% in that time.
Investors will be hoping for strength from Viatris as it approaches its next earnings release, which is expected to be February 28, 2022. In that report, analysts expect Viatris to post earnings of $0.82 per share. This would mark a year-over-year decline of 12.77%. Meanwhile, our latest consensus estimate is calling for revenue of $4.31 billion, up 18.97% from the prior-year quarter.
Investors might also notice recent changes to analyst estimates for Viatris. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. Viatris is currently sporting a Zacks Rank of #3 (Hold).
Looking at its valuation, Viatris is holding a Forward P/E ratio of 4.11. This valuation marks a discount compared to its industry's average Forward P/E of 23.48.
The Medical Services industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 155, which puts it in the bottom 40% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.